medigraphic.com

2016, Number 1

<< Back Next >>

Rev Cuba Endoc 2016; 27 (1)

Neovascular glaucoma, a retinal ischemia complication

Redondo PLR, Maciques RJE, Velázquez PNM

Language: Spanish
References: 31
Page: 93-104
PDF size: 109.21 Kb.


ABSTRACT

Introduction: neovascular glaucoma is the type of secondary glaucoma common in diabetic patients; it is caused by the formation of fibrovascular membrane at the camerular angle as a result of angiogenic stimulus due to ocular ischemiagenerating diseases. The proliferative diabetic retinopathy patients may suffer this difficult-to-treat disease that represents a threat to the vision of a patient.
Objective: to review clinical aspects, pathogenenesis, diagnosis methods and treatment of the neovascular glaucoma with a view to preventing or reducing the vision loss.
Development: neovascular glaucoma is a complication of diabetes mellitus and of other general diseases, which brings about significant reduction of vision and often blindness. The most frequent eye diseases responsible for this are central retinal vein occlusion, proliferative diabetic retinopathy and ocular ischemic syndrome, leading to retinal and choroid ischemia with resulting formation of neovessels.
Conclusions: education aimed at diabetic patient and the adequate therapeutic treatment of the diabetic retinopathy is important to prevent the occurrence of neovascular glaucoma.


REFERENCES

  1. Kim D, Singh A, Annapurna S. Neovascular Glaucoma. En: Shaarawy TM. Glaucoma Medical Diagnosis and Therapy. Saint Louis (EE.UU.): Saunders Elsevier; 2009. p. 409-17.

  2. Sivak-Callcott JA, O’Day DM, Gass JD, Tsai JC. Evidence-based recommendations for the diagnosis and treatment of neovascular glaucoma. Ophthalmology. 2001;108:1767-76.

  3. Mocanu C, Barascu D, Marinescu F. Neovascular glaucoma Retrospective study. Ophthalmologica. 2005;49:58-65.

  4. Horsley MB, Kahook MY. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010;21:112-7.

  5. Tripathi RC, Li J, Tripathi BJ, Chalam KV, Adams AP. Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. Ophthalmology. 1998;105:232-7.

  6. Kohno RI, Hata Y, Mochizuki Y, Arita R, Kawahara R, Kita T, et al. Histopathology of Neovascular Tissue From Eyes with Proliferative Diabetic Retinopathy After Intravitreal Bevacizumab Injection. Am J Ophthalmol. 2010;150:223-9.

  7. Hayreh SS. Neovascular glaucoma. Prog Retin Eye Res. 2007;26:470-5.

  8. Sharma A, D’Amico DJ. Medical and surgical management of central retinal vein occlusion. Int Ophthalmol Clin. 2004;44:1-16.

  9. Engelbert M, Del Priore LV, Lama AA. Neovascular Glaucoma. Contemp Ophthalmology. 2008;7(5):18.

  10. Zanon V, Pinazo MD. Oxidative Stress. Theory of Glaucoma. 2008;17(6):508-9.

  11. Landín Sorí M, López Pérez GR, Rodríguez Bencomo DJ. Comportamiento clínico epidemiológico del glaucoma neovascular en un Servicio de Glaucoma. AMC [serie en Internet]. Jun 2009 [citado 30 de julio de 2015];13(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025- 02552009000300009&lng=es&nrm=iso&tlng=es

  12. The Central Vein Occlusion Study Group. Natural History and Clinical Management of Central Retinal Vein Occlusion. Arch Ophthalmol. 1997;115:486-91.

  13. Haymore JG, Mejico LJ. Retinal vascular occlusion syndromes. Int Ophthalmol Clin. 2009;49:63-79.

  14. Mendrinos E, Machinis TG, Pournaras CJ. Ocular ischemic syndrome. Surv Ophthalmol. 2010;55:2-34.

  15. Eguía MF, Río TM, Capote CA. Manual de diagnóstico y tratamiento en oftalmología. La Habana: Editorial Ciencias Médicas; 2009. p. 343-4.

  16. Palko Z. Therapeutic difficulties in neovascular glaucoma. Romanian Oftalmol. 2006;50(2):736.

  17. Shazly TA, Latina MA. Neovascular Glaucoma: Etiology, Diagnosis and Prognosis. Inf Health Care [serie en Internet]. 2009 [citado 11 de diciembre de 2008];24(2). Disponible en: http://www.tandfonline.com/doi/abs/10.1080/08820530902800801

  18. Löffler KU. Neovascular glaucoma: aetiology, pathogenesis and treatment. Ophthalmologe. 2006 Dec;103(12):105-764.

  19. Holló G. Diabetic neovascularisation and secondary glaucoma. Orv Hetil. 2011 Jul 17;152(29):116-770.

  20. Johnson CA. The Decision Tree in Glaucoma Diagnosis. Rev Optometry. 2009;12(146):1007-17.

  21. Fernández-Vigo J, Castro J, Macarro A. Diabetic iris neovascularization. Natural history and treatment. Acta Ophthalmol Scand. 1997;75:89-93.

  22. Iliev ME, Domig D, Wolf-Schnurrbursch U, Wolf S, Sarra GM. Intravitreal bevacizumab (Avastin) in thetreatment of neovascular glaucoma. Am J Ophthalmol. 2006;142:1054-6.

  23. Saito Y, Higashide T, Takeda H, Murotani E, Ohkubo S, Sugiyama K. Clinical Factors Related to Recurrence of Anterior Segment Neovascularization After Treatment Including Intravitreal Bevacizumab. American Journal of Ophthalmology. 2010;149(6):964-72.

  24. Avidorf FH, Mouser JG, Derick RJ. Rapid improvement of rubeosis iridis from a single Bevacizumab (Avastin) injection. Retina. 2006;26:354-6.

  25. Ichhpujani P, Ramasubramanian A, Kaushik S, Pandav SS. Bevacizumab in glaucoma. Can J Ophthalmol. 2007;42:812-5.

  26. Gunther JB, Altaweel MM. Bevacizumab (Avastin) for the Treatment of Ocular Disease. Survey of Ophthalmology. 2009;54:372-400.

  27. Rush R. Ciliary sulcus Ahmed Glaucoma Valve Tube Placement in Neovascular Glaucoma. Ophthalmic Surg Lasers Imaging. 2009;40:489-2.

  28. Netland P. The Ahmed Glaucoma Valve in Neovascular Glaucoma (An AOS Thesis). Trans Am Ophthalmol Soc. 2009;107:325-42.

  29. Iliev ME, Gerber S. Long-term outcome of trans-scleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007;91:1631-5.

  30. Pokroy R, Greenwald Y. Visual loss after transscleral diode laser cyclophotocoagulation for primary open angle and neovascular glaucoma. Ophthalmic Surg Lasers Imaging. 2008 Jan-Feb;39(1):229.

  31. Martínez Urbay JG, Depestre Pérez BG. Tratamiento del glaucoma absoluto doloroso mediante inyección retrobulbar de Clorpromazina. Rev Mis Milagro [serie en Internet]. 2009 Abr-Jun [citado 19 de junio de 2010];3(2). Disponible en: http://www.misionmilagro.sld.cu/vol3no2/inv3205.php




2020     |     www.medigraphic.com